(Q38058376)

27 August 2017

title

P-glycoprotein imaging in temporal lobe epilepsy: in vivo PET experiments with the Pgp substrate [11C]-verapamil (English)

1 reference

27 August 2017

main subject

temporal lobe epilepsy

1 reference

Maria Feldmann

1

1 reference

27 August 2017

Matthias Koepp

series ordinal

2

1 reference

27 August 2017

publication date

1 November 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

53 Suppl 6

1 reference

27 August 2017

page(s)

60-63

1 reference

Biochemical, cellular, and pharmacological aspects of the multidrug transporter

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

Imaging of P-glycoprotein function and expression to elucidate mechanisms of pharmacoresistance in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

Drug resistance in brain diseases and the role of drug efflux transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

MDR1 gene expression in brain of patients with medically intractable epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1167.2012.03704.X

10.1111/J.1528-1167.2012.03704.X

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference